Qualified non-hospital, outpatient facilities are those that have previously administered monoclonal antibodies or completed a certification through AmerisourceBergen Specialty Division (ASD) and have the capabilities to administer a 3-day course of IV infusion, including patient monitoring and management of adverse events. These entities should contact ASD at C19Therapies@AmerisourceBergen.com or 1-800-746-6273 to order Veklury for nonhospital use. Outpatient centers that have not previously administered monoclonal antibodies will need to complete a verification process for qualification with ASD (Veklury Non-Hospital Access Attestation Form). Most accounts will be able to order within 24 hours of completing this step.
All hospitals should continue ordering through their distributor arrangement with
The
About Veklury
Veklury (remdesivir 100 mg for injection) is a nucleotide analog invented by Gilead, building on more than a decade of the company's antiviral research. Veklury is the antiviral standard of care for the treatment of hospitalized patients with COVID-19. At this time, more than half of patients hospitalized with COVID-19 in
Veklury directly inhibits viral replication inside of the cell by targeting the SARS-CoV-2 viral RNA polymerase. On entering the body Veklury is transformed into the active metabolite remdesivir triphosphate, which is then incorporated into the viral RNA and stops replication of the virus within the host cell. As new SARS-CoV-2 variants of concern emerge around the world, Gilead continuously evaluates the effectiveness of Veklury against viral variants. In vitro laboratory testing in multiple independent studies shows that Veklury retains activity against the Omicron variant. To date, no major genetic changes have been identified in any of the known variants of concern that would significantly alter the viral RNA polymerase targeted by Veklury. Gilead continues to experimentally evaluate the activity of Veklury against identified SARS-CoV-2 variants through in vitro antiviral testing. Veklury's antiviral activity has been confirmed in vitro against all major previously identified variants of SARS-CoV-2 including Alpha, Beta, Gamma, Delta, Epsilon and Omicron.
Veklury is approved or authorized for temporary use in approximately 50 countries worldwide. To date, Veklury and generic remdesivir have been made available to more than 10 million patients around the world, including 7 million people in 127 middle- and low-income countries through Gilead's voluntary licensing program. These licenses currently remain royalty-free, reflecting Gilead's existing commitment to enabling broad patient access to remdesivir.
About
Forward-Looking Statements
This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to effectively manage the supply and distribution of Veklury, including for the use of Veklury in non-hospitalized patients in
Veklury, Gilead and the Gilead logo are registered trademarks of
For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
(C) 2022 Electronic News Publishing, source